A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

Exclusion Criteria

• •Unable to be randomized prior to coronary revascularization or fibrinolysis for the qualifying MI.
• •Current severe heart failure or shock
• •Ongoing clinical instability
• •History of chronic liver disease
• •Known severe renal impairment
• •Any condition, other than vascular disease, with life expectancy \<1 year that might prevent the subject from completing the study.
• •Known active tuberculosis, HIV, active opportunistic or life threatening infections.
• •Vaccination with a live attenuated vaccine within 6 weeks of randomization.
• •Concomitant use of cytotoxic chemotherapy for cancer or known ongoing or anticipated use of chronic severe immunosuppressive agents
• •Positive pregnancy test or is known to be pregnant or lactating
• •Known alcohol or drug abuse within the past 6 months
• •Any current mental condition, which may affect study compliance or prevent understanding of the aims, investigational procedures or possible consequences of the study.
• •Participation in a study of an investigational medication within the past 30 days.
• •Anticipated inability to comply with any study procedures, including participation in study visits according to the visit schedule through 24 weeks.
• •Use of another investigational product within 30 days or 5 half-lives (whichever is longer) or according to local regulations, or currently participating in a study of an investigational device. Subjects must be randomized only one time in this investigational study
• •Any other reason the investigator deems the subject to be unsuitable for the study